LAG-3 is highly co-expressed with PD-1 in tumor-infiltrating CD4+ and CD8+ T lymphocytes, and dual inhibition of LAG-3 and PD-1 has demonstrated synergistic antitumor activity in preclinical studies [16]. Here, CD8A is linked to neoplasm.